Aberdeen Asset Management (LON:ADN) Rating Reaffirmed
In a very recent research note revealed to investors and clients on 4 December, Charles Stanley kept steady their “Buy” rating on Aberdeen Asset Management (LON:ADN) shares.
From a total of 17 analysts covering Aberdeen Asset Management PLC (LON:ADN) stock, 3 rate it a ”Buy”, 5 a “Sell”, and 10 a ”Hold”. This means that 17% of the ratings are positive. The highest target price is GBX 430 while the lowest target price is GBX 260. The mean of all analyst targets is GBX 329.65 with a 18.25% above today’s (GBX 304) stock price. Aberdeen Asset Management PLC was the topic of 46 analyst reports since July 23, 2015 according to the firm StockzIntelligence Inc. RBC Capital Markets maintained shares on December 3 with “Underperform” rating. JP Morgan maintained shares with “Neutral” rating and GBX 315 target share price in a report from a December 1. BNP Paribas maintained ADN stock in a recent report from December 1 with “Underperform” rating. Barclays Capital maintained the rating on December 1. Barclays Capital has a “Equal Weight” rating and a GBX 350 price target on shares. Finally, Citigroup maintained the stock with “Neutral” rating in a report issued on a December 1.
The stock increased 0.93% or GBX 2.8 on December 4, striking GBX 304. Approximately 5.11 million shares of stock traded hands or 31.70% up from the average. Aberdeen Asset Management plc (LON:ADN) has declined 32.36% since May 7, 2015 and is downtrending. It has underperformed by 29.58% the S&P500.
Aberdeen Asset Management PLC is United Kingdom asset management company. The company has a market cap of 4.01 billion GBP. The Firm manages assets for both institutional and retail clients. It has 13.95 P/E ratio. The firm invests across the four main asset classes of equity, fixed income, property and alternative investment strategies.